Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALUR

Allurion Technologies Inc

Mar 21 • 04:00PM ET

3.58

Dollar change +1.30
Percentage change 57.02	%

Healthcare • Medical Devices • USA • NYSE

Peers: ABT SYK MDT BSX ILMN BDX ZBH DXCM PODD TNDM

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.89	Insider Own	13.00%	Shs Outstand	5.96M	Perf Week	50.42%
Market Cap	21.34M	Forward P/E	-	EPS next Y	-5.21	Insider Trans	0.00%	Shs Float	5.19M	Perf Month	-0.56%
Income	-24.76M	PEG	-	EPS next Q	-5.70	Inst Own	24.75%	Short Float	2.42%	Perf Quarter	-54.58%
Sales	34.75M	P/S	0.61	EPS this Y	81.19%	Inst Trans	0.85%	Short Ratio	0.08	Perf Half Y	-77.65%
Book/sh	-25.16	P/B	-	EPS next Y	52.07%	ROA	-28.89%	Short Interest	0.13M	Perf Year	-93.52%
Cash/sh	4.81	P/C	0.74	EPS next 5Y	56.28%	ROE	-1715.20%	52W Range	2.15 - 98.75	Perf YTD	-66.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-96.37%	Beta	-0.44
Dividend TTM	-	Quick Ratio	2.09	Sales past 5Y	-5.58%	Gross Margin	71.80%	52W Low	66.51%	ATR (14)	0.58
Dividend Ex-Date	-	Current Ratio	2.33	EPS Y/Y TTM	87.95%	Oper. Margin	-168.66%	RSI (14)	53.22	Volatility	14.73% 11.21%
Employees	252	Debt/Eq	-	Sales Y/Y TTM	11.53%	Profit Margin	-71.24%	Recom	1.50	Target Price	28.62
Option/Short	No / No	LT Debt/Eq	-	EPS Q/Q	74.10%	Payout	-	Rel Volume	46.41	Prev Close	2.28
Sales Surprise	-37.23%	EPS Surprise	23.29%	Sales Q/Q	-70.51%	Earnings	Mar 26 BMO	Avg Volume	1.60M	Price	3.58
SMA20	30.85%	SMA50	-12.09%	SMA200	-76.34%	Trades		Volume	74,231,269	Change	57.02%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-02-24	Initiated	TD Cowen	Buy	$2
Sep-06-24	Initiated	ROTH MKM	Buy	$2
Feb-09-24	Initiated	Jefferies	Buy	$5

Mar-20-25 04:59PM	Allurion surges on weight loss data from gastric balloon, GLP-1 combo treatment (SeekingAlpha) -5.00% +57.02%
04:05PM	Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence (Business Wire)
Mar-12-25 04:05PM	Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025 (Business Wire) +8.09%
Mar-04-25 04:05PM	Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity (Business Wire) -8.77%
Feb-25-25 04:05PM	Allurion to Participate in Upcoming Investor Conferences (Business Wire) +7.06%
04:05PM	Loading…
Feb-20-25 04:05PM	Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline (Business Wire) -7.69%
Feb-19-25 09:03AM	Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline (Business Wire) -30.11%
Feb-18-25 08:30AM	Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity (Business Wire) +8.35%
Feb-13-25 08:30AM	Allurion Relaunches in France (Business Wire)
Feb-10-25 09:55AM	How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67% (Zacks) -8.61%
Jan-24-25 04:15PM	Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk (Investor's Business Daily) +134.86% -21.17%
11:28AM	Allurion Catapults Nearly 200% On Its Plans To Outdo Eli Lilly, Novo Nordisk (Investor's Business Daily)
10:32AM	Allurion Stock Skyrockets 80% After Hours Following Clinical Study Announcement (GuruFocus.com)
09:30AM	Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market (Business Wire)
Jan-23-25 03:48PM	Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program (Business Wire) +21.31%
08:30AM	Loading…
Jan-21-25 08:30AM	Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity (Business Wire)
Jan-14-25 09:18AM	Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024 (Business Wire) +5.72%
Jan-08-25 08:00AM	Allurion Announces Positive Topline Results From AUDACITY Trial (Business Wire) -7.42%
Dec-24-24 07:00AM	Allurion Technologies, Inc. Announces Reverse Stock Split (Business Wire) +12.33%
Dec-19-24 03:57PM	FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next (Yahoo Finance) -9.74%
Dec-02-24 08:00AM	Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance (Business Wire)
Nov-25-24 02:51PM	Allurion launches compounded GLP-1 program as FDA aims to ends access (Yahoo Finance)
02:51PM	Allurion launches compounded GLP-1 program as FDA aims to end access (Yahoo Finance)
08:00AM	Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program (Business Wire)
Nov-13-24 08:00AM	Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -26.34%
Nov-04-24 08:10AM	Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Societys Annual Conference (Business Wire)
Oct-30-24 08:30AM	Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024 (Business Wire) -5.13%
Oct-23-24 08:00AM	Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon (Business Wire)
Oct-09-24 08:00AM	Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss (Business Wire)
Oct-01-24 08:04AM	Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss (Business Wire)
05:30PM	Loading…
Sep-05-24 05:30PM	Allurion Receives Continued Listing Standards Notice from NYSE (Business Wire) -5.56%
08:00AM	Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity (Business Wire)
Sep-03-24 08:00AM	Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors (Business Wire)
Aug-28-24 08:28AM	Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program (Business Wire) +5.42%
Aug-20-24 08:00AM	Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial (Business Wire) +5.02%
Aug-15-24 04:05PM	Allurion Receives Continued Listing Standards Notice from NYSE (Business Wire)
Aug-13-24 08:00AM	Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-16-24 04:05PM	Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024 (Business Wire) -6.37%
Jun-28-24 09:06AM	Allurion Announces Pricing of $20 million Public Offering and Concurrent Private Placement (Business Wire) -23.26%
Jun-26-24 08:36AM	Allurion Announces Launch of Offering of Common Stock and Warrants (Business Wire) -16.58%
Jun-20-24 03:49PM	Why Is Allurion (ALUR) Stock Up 140% Today? (InvestorPlace) +145.28%
08:00AM	Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss (Business Wire)
Jun-14-24 01:44PM	Allurion (ALUR) Unveils Positive Data for Its Balloon Therapy (Zacks) -11.51%
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
09:35AM	Allurion Technologies, Inc. (ALUR) Loses -38.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:00AM	Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery (Business Wire)
Jun-05-24 08:00AM	Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer (Business Wire)
May-30-24 08:00AM	Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s (Business Wire) -5.62%
May-29-24 04:05PM	Allurion to Participate in Two Upcoming Investor Conferences in June 2024 (Business Wire)
May-15-24 08:00AM	Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss (Business Wire) -9.00%
May-14-24 12:53PM	ALUR Stock Earnings: Allurion Technologies Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +8.76%
08:00AM	Allurion Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-02-24 08:00AM	Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including First-Ever 3-Year Weight Maintenance Survey (Business Wire) -6.38%
Apr-30-24 08:30AM	Allurion Announces Preliminary First Quarter 2024 Results (Business Wire)
Apr-17-24 08:31AM	Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments (Business Wire) -8.05%
Apr-04-24 08:00AM	Allurion Expands Virtual Care Suite to the United States (Business Wire) +78.03%
Mar-21-24 12:53PM	ALUR Stock Earnings: Allurion Technologies Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:00AM	Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (Business Wire)
Mar-13-24 08:30AM	Allurion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference (Business Wire) +6.04%
Mar-12-24 08:00AM	Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair (Business Wire)
Mar-04-24 08:30AM	Allurion to Report Fourth Quarter 2023 Financial Results on March 21, 2024 (Business Wire) -8.31%
Feb-20-24 04:05PM	Allurion to Participate in Cowens 44th Annual Health Care Conference (Business Wire) +7.47%
Feb-08-24 08:30AM	Allurion to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference (Business Wire)
Jan-29-24 08:00AM	Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies (Business Wire)
Jan-23-24 09:04AM	Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss (Business Wire)
08:15AM	World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss (Business Wire)
Jan-17-24 08:00AM	Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships (Business Wire)
Jan-11-24 08:00AM	Allurion Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities (Business Wire)
Jan-08-24 08:00AM	Allurion Announces Preliminary Fourth Quarter and Full Year 2023 Results and Provides 2024 Outlook (Business Wire)
Jan-05-24 08:00AM	New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program (Business Wire)
Jan-02-24 08:00AM	Allurions Digital Platform Gains Traction with Expanded Strategic Partnership (Business Wire) -5.61%
Nov-13-23 08:00AM	Allurion Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-06-23 04:05PM	Allurion to Participate in the Jefferies London Healthcare Conference (Business Wire) -7.08%
08:00AM	Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023 (Business Wire)
Oct-11-23 08:00AM	Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon (Business Wire)
Oct-04-23 08:00AM	Allurion Announces Acceptance of Five Abstracts for Presentation at Obesity Week 2023 (Business Wire)
Sep-18-23 08:00AM	Allurion Featured at the 2023 International Bariatric Club Oxford University World Congress (Business Wire) +8.00%
Aug-29-23 08:00AM	Allurion Introduces Coach Iris: A 24/7 Generative AI-Powered Weight Loss Coach (Business Wire)
Aug-28-23 08:00AM	Allurion Announces Acceptance of Nine Scientific Presentations at IFSO 2023 World Congress (Business Wire)
Aug-04-23 01:33PM	Allurion sees tailwind from weight loss drug frenzy (Yahoo Finance)

Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is headquartered in Natick, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALUR

Allurion Technologies Inc

Upgrade your FINVIZ experience